Preparation of (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl) imidazo [1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide and pharmaceutically acceptable salts thereof

Preparation of (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl) imidazo [1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide and pharmaceutically acceptable salts thereof

The present invention relates to 6-5 membered fused pyridine ring compounds according to formula Ior a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 mem...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: STERRENBURG Jan-Gerard, JANS Christiaan Gerardus Johannes Maria, REWINKEL Johannes Bernardus Maria, BARF Tjeerd A, MAN de Adrianus Petrus Antonius, RAAIJMAKERS Hans C.A, WIJKMANS Jacobus C.H.M, OUBRIE Arthur A
Format: Patent
Sprache:eng ; heb
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator STERRENBURG Jan-Gerard
JANS Christiaan Gerardus Johannes Maria
REWINKEL Johannes Bernardus Maria
BARF Tjeerd A
MAN de Adrianus Petrus Antonius
RAAIJMAKERS Hans C.A
WIJKMANS Jacobus C.H.M
OUBRIE Arthur A
description The present invention relates to 6-5 membered fused pyridine ring compounds according to formula Ior a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IL266894B</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IL266894B</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IL266894B3</originalsourceid><addsrcrecordid>eNqFjLEKwjAURbs4iPoL8sYWfEOtiq6KouDg4CZSXttXDKRJSNKh_R1_1BQER6cL5xzuOHrfLBuy5IVWoGuIXYIrjLdIjVAaM4xTLFqPS-yU7qTprNVSVEINRCYgGlFRr-GRLtZIz-CpDzIdJCqMA_jVBas-_FYMpCowL7INldx6UZKUHVBZsvFUSAZH0jvwL7as62k0qkk6nn13Es1Px_vhjGx0zs6ED8U-v1yXm812t9pnf4MPTH5Rgg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Preparation of (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl) imidazo [1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide and pharmaceutically acceptable salts thereof</title><source>esp@cenet</source><creator>STERRENBURG Jan-Gerard ; JANS Christiaan Gerardus Johannes Maria ; REWINKEL Johannes Bernardus Maria ; BARF Tjeerd A ; MAN de Adrianus Petrus Antonius ; RAAIJMAKERS Hans C.A ; WIJKMANS Jacobus C.H.M ; OUBRIE Arthur A</creator><creatorcontrib>STERRENBURG Jan-Gerard ; JANS Christiaan Gerardus Johannes Maria ; REWINKEL Johannes Bernardus Maria ; BARF Tjeerd A ; MAN de Adrianus Petrus Antonius ; RAAIJMAKERS Hans C.A ; WIJKMANS Jacobus C.H.M ; OUBRIE Arthur A</creatorcontrib><description>The present invention relates to 6-5 membered fused pyridine ring compounds according to formula Ior a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.</description><language>eng ; heb</language><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220401&amp;DB=EPODOC&amp;CC=IL&amp;NR=266894B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25546,76297</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220401&amp;DB=EPODOC&amp;CC=IL&amp;NR=266894B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>STERRENBURG Jan-Gerard</creatorcontrib><creatorcontrib>JANS Christiaan Gerardus Johannes Maria</creatorcontrib><creatorcontrib>REWINKEL Johannes Bernardus Maria</creatorcontrib><creatorcontrib>BARF Tjeerd A</creatorcontrib><creatorcontrib>MAN de Adrianus Petrus Antonius</creatorcontrib><creatorcontrib>RAAIJMAKERS Hans C.A</creatorcontrib><creatorcontrib>WIJKMANS Jacobus C.H.M</creatorcontrib><creatorcontrib>OUBRIE Arthur A</creatorcontrib><title>Preparation of (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl) imidazo [1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide and pharmaceutically acceptable salts thereof</title><description>The present invention relates to 6-5 membered fused pyridine ring compounds according to formula Ior a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFjLEKwjAURbs4iPoL8sYWfEOtiq6KouDg4CZSXttXDKRJSNKh_R1_1BQER6cL5xzuOHrfLBuy5IVWoGuIXYIrjLdIjVAaM4xTLFqPS-yU7qTprNVSVEINRCYgGlFRr-GRLtZIz-CpDzIdJCqMA_jVBas-_FYMpCowL7INldx6UZKUHVBZsvFUSAZH0jvwL7as62k0qkk6nn13Es1Px_vhjGx0zs6ED8U-v1yXm812t9pnf4MPTH5Rgg</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>STERRENBURG Jan-Gerard</creator><creator>JANS Christiaan Gerardus Johannes Maria</creator><creator>REWINKEL Johannes Bernardus Maria</creator><creator>BARF Tjeerd A</creator><creator>MAN de Adrianus Petrus Antonius</creator><creator>RAAIJMAKERS Hans C.A</creator><creator>WIJKMANS Jacobus C.H.M</creator><creator>OUBRIE Arthur A</creator><scope>EVB</scope></search><sort><creationdate>20220401</creationdate><title>Preparation of (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl) imidazo [1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide and pharmaceutically acceptable salts thereof</title><author>STERRENBURG Jan-Gerard ; JANS Christiaan Gerardus Johannes Maria ; REWINKEL Johannes Bernardus Maria ; BARF Tjeerd A ; MAN de Adrianus Petrus Antonius ; RAAIJMAKERS Hans C.A ; WIJKMANS Jacobus C.H.M ; OUBRIE Arthur A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IL266894B3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; heb</language><creationdate>2022</creationdate><toplevel>online_resources</toplevel><creatorcontrib>STERRENBURG Jan-Gerard</creatorcontrib><creatorcontrib>JANS Christiaan Gerardus Johannes Maria</creatorcontrib><creatorcontrib>REWINKEL Johannes Bernardus Maria</creatorcontrib><creatorcontrib>BARF Tjeerd A</creatorcontrib><creatorcontrib>MAN de Adrianus Petrus Antonius</creatorcontrib><creatorcontrib>RAAIJMAKERS Hans C.A</creatorcontrib><creatorcontrib>WIJKMANS Jacobus C.H.M</creatorcontrib><creatorcontrib>OUBRIE Arthur A</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>STERRENBURG Jan-Gerard</au><au>JANS Christiaan Gerardus Johannes Maria</au><au>REWINKEL Johannes Bernardus Maria</au><au>BARF Tjeerd A</au><au>MAN de Adrianus Petrus Antonius</au><au>RAAIJMAKERS Hans C.A</au><au>WIJKMANS Jacobus C.H.M</au><au>OUBRIE Arthur A</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Preparation of (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl) imidazo [1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide and pharmaceutically acceptable salts thereof</title><date>2022-04-01</date><risdate>2022</risdate><abstract>The present invention relates to 6-5 membered fused pyridine ring compounds according to formula Ior a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; heb
recordid cdi_epo_espacenet_IL266894B
source esp@cenet
title Preparation of (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl) imidazo [1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide and pharmaceutically acceptable salts thereof
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A03%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=STERRENBURG%20Jan-Gerard&rft.date=2022-04-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIL266894B%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true